Bisdemethoxycurcumin (BDMC) combined with anti-PD-L1 antibody significantly prolonged the survival of bladder cancer mice, increased CD8+ T cells number, and promoted the secretion of IFN-γ, granzyme B, and perforin, improving the function of CD8+T cells. This evidence concerns the gene CD8A and urinary bladder cancer.